Clinical and biochemical outcomes of type 2 diabetes mellitus in Canterbury, New Zealand: A 6-year cohort study

Diabetes Research and Clinical Practice

Volumn 40, Issue 3, 1998, Pages 167-173

  Florkowski, Christopher M ^a   Scott, Russell S ^a   Moir, Cameron L ^a   Graham, Patrick J ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Outcomes; Retinopathy; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RETINOPATHY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; TIME FACTORS;

EID: 0032102724     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00048-5     Document Type: Article

References (17)

1. Simmons D. Diabetes and its complications in New Zealand: an epidemiological perspective. N.Z. Med. J. 109:1996;245-247.
2. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986.
3. Chen M.S., Kao C.S., Chen C.J., Tai T.Y. Incidence and progression of diabetic retinopathy among non-insulin-dependent diabetic subjects: a 4-year follow-up. Int. J. Epidemiol. 24(4):1995;787-795.
4. Morisaki N., Watanabe S., Kobayashi J.et al. Diabetic control and progression of retinopathy in elderly patients: a five-year follow-up study. J. Am. Geriatr. Soc. 42:1994;142-145.
5. West K.M., Ahuja M.M.S., Bennett P.H.et al. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care. 6:1983;361-369.
6. Stern M.P., Mitchell B.D., Haffner S.M., Hazuda H.P. Does glycaemic control of type II diabetes suffice to control diabetic dyslipidaemia? Diabetes Care. 15(5):1992;638-644.
7. 1c with basal insulin supplement, sulfonylureas, or biquanide therapy in maturity-onset diabetes. Diabetes. 34:1985;793-798.
8. Turner R., Cull C., Holman R. UK Prospective Diabetes Study: 17. A 9-year update of a randomized, controlled trial on the effect of improved metabolic control of complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 124(1, part 2):1996;136-145.
9. D.W. Beaven, R.S. Scott, The organisation of diabetes care, The Diabetes Annual, 12th ed., Elsevier, Amsterdam, 1986, pp. 284-287.
10. Florkowski C.M., Scott R.S., Moir C.L., Graham P.J. Lipid but not glycaemic parameters predict mortality from Type 2 diabetes mellitus in Canterbury, New Zealand. Diabetic Med. 15:1998;386-392.
11. Lever M., May P.C., Andre C.M. Automated fluorimetric determination of furfurals. Anal. Biochem. 144:1985;6-14.
12. Wilson P., Cupples L.A., Kannel W. Is hyperglycaemia associated with cardiovascular disease? The Framingham study. Am. Heart J. 121:1991;586-590.
13. Kuusisto J., Mykkanen L., Pyorala K., Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 43:1994;960-967.
14. New Zealand Society for the Study of Diabetes Core components for a diabetes service. N.Z. Med. J. 108:1996;434-435.
15. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
16. Bressier R., Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care. 15(6):1992;792-805.
17. Fujimoto W.Y. A national multicenter study to learn whether type II diabetes can be prevented: The Diabetes Prevention Program. Clin. Diabetes. 15(1):1997;13-15.